Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

PQ Pharmacy, LLC

Has PQ Pharmacy, LLC received an FDA warning letter? Yes. FDA issued a warning letter dated October 10, 2025.

Letter facts

Letter date
October 10, 2025 (2025-10-10)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Compounding Pharmacy
Products named
Prednisolone/Moxifloxacin HCl/Bromfenac PF Sterile Ophthalmic SolutionPrednisolone/Moxifloxacin HCl PF Sterile Ophthalmic Solution
Violation categories
Unapproved new drugMisbrandingCompounding outside 503A/503BCGMP / insanitary conditions

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

Compounding outside 503A/503B

FDA says this pharmacy's compounded products did not meet the conditions that let pharmacies compound drugs without FDA approval. A warning letter is FDA's notice of what it believes are significant violations; the company can respond.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

Factual Violation Summary

FDA says sterile compounded ophthalmic drugs were produced under insanitary conditions with poor aseptic technique, inadequate airflow and smoke studies, and CGMP failures in procedures, contamination control, environmental monitoring, and investigations. Products also lacked established names, adequate adverse event reporting, approvals, and adequate directions for use.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Adulterated drug products (insanitary conditions, FDCA 501(a)(2)(A))
  • CGMP violations (FDCA 501(a)(2)(B); 21 CFR 211.100(a), 211.113(b), 211.42(c)(10)(iv), 211.192)
  • Failure to meet section 503B conditions (missing established drug name; inadequate adverse event reporting procedures)
  • Unapproved new drug products (FDCA 505(a), 301(d))
  • Misbranded drug products (FDCA 502(f)(1), 301(a), 301(k))

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.